Rejuvenate Bio Appoints Kaye Spratt as SVP of Regulatory Affairs and Kristy J. Brown, Ph.D. as VP of Preclinical Development and Translational Science

Rejuvenate Bio

Targeting the core drivers of chronic age-related diseases to reverse pre-existing conditions in humans

Published Apr 12, 2023

SAN DIEGO - April 12, 2023 - Rejuvenate Bio, today announced the appointment of Kaye Spratt as SVP of Regulatory Affairs and Kristy J. Brown, Ph.D. as VP of Preclinical Development and Translational Science.

“I’m thrilled to welcome Kaye and Kristy, as we continue to expand our team and advance our novel gene therapy for humans and canines with age-related diseases,” said Daniel Oliver, CEO & Co-Founder, Rejuvenate Bio. “Both executives bring invaluable expertise, as we continue to advance our pipeline to target the core drivers of chronic age-related diseases.”

No alt text provided for this image — Kaye Spratt

Kaye Spratt joins Rejuvenate Bio as Senior Vice President (SVP) of Regulatory Affairs. She brings more than 24 years of experience in life sciences regulatory affairs to Rejuvenate. Prior to joining Rejuvenate Bio, Kaye was the Chief Regulatory Officer at BridgeBio Gene Therapy. Kaye was also SVP at BridgeBio, and VP of Regulatory and Quality at Abeona Therapeutics. She was at Sangamo as Director of Preclinical and Assay Development for more than 17 years. Kaye holds a degree in microbiology from Meharry Medical College.

Kristy J. Brown, Ph.D. joins Rejuvenate Bio as VP Preclinical Development and Translational Science. Prior to joining the company, Kristy was VP, Head of Translational Development at Solid Biosciences, where she spent more than 6 years at the company supporting gene therapy drug development. She was also a faculty member at George Washington University with a laboratory at the Children’s National Health System for more than 7 years. Kristy holds a B.S in Chemistry from Loyola University, Maryland, and a Ph.D. in Chemistry from the University of Maryland, College Park.

About Rejuvenate Bio

Rejuvenate Bio is a spinout from the Wyss Institute at Harvard focused on targeting the core drivers of chronic age-related diseases. Rejuvenate Bio utilizes gene therapy, proprietary targets, and tools to bring treatments to patients suffering from age-related conditions. The company is developing a pipeline of therapies with applications in cardiac and metabolic disease. The company raised a Series A financing in 2021 led by Kendall Capital Partners, Digitalis Ventures, KdT Ventures and V Capital. Rejuvenate Bio is based in San Diego for more information, visit www.rejuvenatebio.com.